



APRIL 19, 2023

## **Apellis announces discontinuation of open-label period of the MERIDIAN study**

Apellis announced that people living with ALS will discontinue investigational treatment with systemic pegcetacoplan in the open-label period of the MERIDIAN study.

The decision was made following an unblinded review of the available data by an independent data monitoring committee.

The committee concluded the available data did not support continuation of treatment.

Their recommendation was not based on any safety concerns.

All patients have now completed the randomized treatment period, and Apellis will analyze the data as planned.

Next steps for the program will be decided after the planned analysis is completed.

Apellis wants to thank all the patients (pALS) and their caregivers (cALS) who participated in the study and appreciate the partnership with the broader ALS community.

While they are disappointed in this outcome, they are committed to continue their worktogether as they analyze the data generated from this study.

**SOURCE: Apellis and Sobi ALS community statement**

**European organization for Professionals and Patients with ALS (EUpALS) ivzw**

Registered office: Vaartkom 17, B-3000 Leuven, Belgium

Enterprise number BE 0684.923.631 – Commercial Tribunal of Leuven

Tel: +32 (0)16-23 95 82 – [info@ALS.eu](mailto:info@ALS.eu) – [www.ALS.eu](http://www.ALS.eu)